Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RADOO1 (Everolimus)

Trial Profile

Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RADOO1 (Everolimus)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Everolimus (Primary)
  • Indications Renal cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 08 Jun 2010 Study details were reported at ASCO 2010.
    • 02 Sep 2009 Planned end date (Dec 2011) added as reported by ClinicalTrials.gov.
    • 02 Sep 2009 Actual initiation date (Aug 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top